National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 1411918

History of Changes from the VAERS Wayback Machine

First Appeared on 7/23/2021

VAERS ID: 1411918
VAERS Form:2
Vaccin­ation / Manu­facturer Lot / Dose Site / Route

Administered by: Other      Purchased by: ??
Symptoms: Dizziness, Nausea

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? Yes
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Cardiac failure; Hypertension
Diagnostic Lab Data:
CDC 'Split Type': JPPFIZER INC2021655935

Write-up: Dizziness; Nausea; This is a spontaneous report from a contactable nurse received via COVID-19 Adverse Event Self-Reporting Solution (COVAES). The patient was a non-pregnant 77-year-old female. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Other medical history included hypertension and cardiac failure. On 02Jun2021at 12:45 (the day of vaccination), the patient received the first single dose (also reported as 6th dose, pending clarification) of BNT162B2 (COMIRNATY, Solution for injection, Lot number FA5829, Expiration date 31Aug2021) intramuscular in the left arm for COVID-19 immunization. On 04Jun2021 at 5:00 (1 day 16 hours 15 minutes after the vaccination), the patient experienced dizziness and nausea. The outcome of the event was recovered with treatment by drip infusion. The reporter stated the events results in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19.; Sender''s Comments: A causal association between BNT162B2 and the reported events cannot be excluded based on temporal relationship. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to RAs, Ethics Committees, and Investigators, as appropriate.

New Search

Link To This Search Result:

Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166